Cancer genomic biomarkers in human malignancies

JOINT EVENT:25^th World Congress on CANCER SCIENCE AND THERAPY & 10^th World Congress on BIOMARKERS & CLINICAL RESEARCH

October 18-20, 2017 Baltimore, USA

Jianhua Luo

University of Pittsburgh School of Medicine, USA

Keynote: J Cancer Sci Ther

Abstract :

Cancer remains one of the most lethal diseases for human. In recent studies, genomic analysis has rapidly advanced the diagnostics of human cancers. Our result showed that combination of genome copy number variance, genome methylation pattern and novel fusion transcripts specific for cancer achieved high accuracy in predicting clinical outcomes of human cancers. Interestingly, some of these fusion genes are also present in a variety of human malignancies. Some of these fusion gene products trigger new pathways that are essential for carcinogenesis in multiple human cancers and create novel functions that are not present in wild type gene counterparts. Some of these novel fusion genes are highly targetable. Treatment of cancers with drugs specific for these genes and their signaling pathways produced dramatic improvement of metastasis and survival rate of animals xenografted with cancers positive for these fusion genes. Our analyses suggest that targeting therapy for fusion genes holds promise as an effective treatment for human cancers.

Biography :

Jianhua Luo has been studying molecular mechanism related to human malignancies in the last 24 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 16 years, he has been largely focusing on genetic and molecular mechanism of human prostate cancer and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, his group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research.